JASPER THERAPEUTICS, INC. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- JASPER THERAPEUTICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2024-12-31 was $30.00K.
- JASPER THERAPEUTICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2024-09-30 was $9.00K, a 75.00% decline year-over-year.
- JASPER THERAPEUTICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2024-06-30 was $136.00M, a 42400.00% increase year-over-year.
- JASPER THERAPEUTICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2024-03-31 was $154.00K, a 381.25% increase year-over-year.
- JASPER THERAPEUTICS, INC. stock issued during period, value, stock options exercised for fiscal 2024 was $329.00K, a 15.21% decline from fiscal 2023.
- JASPER THERAPEUTICS, INC. stock issued during period, value, stock options exercised for fiscal 2023 was $388.00K, a 1337.04% increase from fiscal 2022.
- JASPER THERAPEUTICS, INC. stock issued during period, value, stock options exercised for fiscal 2022 was $27.00K, a 88.51% decline from fiscal 2021.
- JASPER THERAPEUTICS, INC. stock issued during period, value, stock options exercised for fiscal 2021 was $235.00K, a 343.40% increase from fiscal 2020.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2024-12-31 | $30.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $329.00K 10-K · filed 2026-03-30 |
| 2024-09-30 | $9.00K 10-Q · filed 2025-11-10 | $136.16M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $136.00M 10-Q · filed 2025-08-13 | $136.19M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $154.00K 10-Q · filed 2025-05-12 | $510.00K derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $388.00K 10-K · filed 2025-02-28 |
| 2023-09-30 | $36.00K 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $320.00K 10-Q · filed 2024-08-13 | |
| 2023-03-31 | $32.00K 10-Q · filed 2024-05-14 | |
| 2022-12-31 | $27.00K 10-K · filed 2024-03-05 | |
| 2022-09-30 | $1.00K 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $13.00K 10-Q · filed 2023-11-09 | |
| 2022-03-31 | $13.00K 10-Q · filed 2023-11-09 | |
| 2021-12-31 | $235.00K 10-K · filed 2023-03-08 | |
| 2021-09-30 | $132.00K 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $68.00K 10-Q · filed 2022-11-10 | |
| 2021-03-31 | $2.00K 10-Q · filed 2022-11-10 | |
| 2020-12-31 | $53.00K 10-K · filed 2022-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |